Loading clinical trials...
Loading clinical trials...
A Two-Part Study to Evaluate the Bioavailability of BMS-626529 Administered as Prodrug BMS-663068 From Prototype Low-Dose Extended-Release Tablets (Part 1) and Prototype Multi-Particulate Formulations (Part 2) Relative to the 600 mg Extended Release Tablet in Healthy Subjects
Conditions
Interventions
BMS-663068
Locations
1
United Kingdom
GSK Investigational Site
Nottingham, United Kingdom
Start Date
August 3, 2015
Primary Completion Date
November 5, 2015
Completion Date
November 5, 2015
Last Updated
September 11, 2017
NCT06719310
NCT02831673
NCT02075593
NCT01231516
NCT02178592
NCT02415595
Lead Sponsor
ViiV Healthcare
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions